PAVmed (NASDAQ:PAVM – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
19.9% of PAVmed shares are held by institutional investors. Comparatively, 2.2% of NexGel shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 23.4% of NexGel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares PAVmed and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | -21,914.12% | -146.19% | -18.39% |
| NexGel | -28.54% | -64.29% | -29.64% |
Risk & Volatility
Valuation and Earnings
This table compares PAVmed and NexGel”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $70,000.00 | 90.00 | $400,000.00 | ($37.40) | -0.17 |
| NexGel | $11.42 million | 0.46 | -$3.00 million | ($0.40) | -1.41 |
PAVmed has higher earnings, but lower revenue than NexGel. NexGel is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for PAVmed and NexGel, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| NexGel | 1 | 0 | 1 | 0 | 2.00 |
PAVmed currently has a consensus price target of $56.00, indicating a potential upside of 788.89%. NexGel has a consensus price target of $2.00, indicating a potential upside of 253.36%. Given PAVmed’s higher probable upside, analysts plainly believe PAVmed is more favorable than NexGel.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
